

Medical Screening and Surveillance for 1,3-Butadiene

29 CFR 1910.1051(k)

Program Administration:

1. Without cost or loss of pay to employee and at a reasonable time and place
2. Performed or administered by a physician or other licensed health care professional
3. Lab tests conducted by an accredited laboratory

What is Provided to Physician or Other Licensed Health Care Professional:

1. A copy of 29 CFR 1910.1051 including the appendices
2. A description of the employee's duties as they relate to BD exposure
3. The employee's BD exposure level, including exposure in an emergency
4. A description of PPE used or to be used
5. Information, when available, from previous employment-related medical evaluations

What is Provided by Physician or Other Licensed Health Care Professional:

1. A written medical opinion to both employer and employee, within 15 business days of the evaluation, as to
 - a. Whether the employee has any detected medical conditions that would increase health risk from exposure to BD
 - b. Any recommended limitations upon the employee's exposure to BD
 - c. A statement that the employee has been informed of the results of the medical evaluation and any medical conditions resulting from BD exposure that require further explanation or treatment
2. Referral of employee to an appropriate specialist for evaluation of any non-occupational abnormalities of the hematopoietic or reticuloendothelial systems

Medical Surveillance:

1. Employer must periodically review all aggregated (personal identifiers removed) data from medical screening (as detailed below), to ascertain whether the health of the employee population is adversely affected by exposure to BD
2. Information from such reviews must be disseminated to covered employees

Frequency and Content of Screening:

<u>Employee Group</u>	<u>Frequency</u>	<u>Content</u>
<p>Employees with current exposure to BD: \$ AL \$ 30 days/ year <u>or</u> \$ PELs \$ 10 days/year</p>	<p><i>a)</i> Health questionnaire and CBC: annually <i>b)</i> Physical examination: * Initial exam * Before job with BD exposure * Every 3 years after initial * At discretion of licensed health care professional * At reassignment to job < AL if \$ 12 months since last exam * At termination of employment if \$ 12 months since last exam</p>	<p><i>a)</i> Baseline and annual updated health questionnaire: * Hematopoietic and reticulo-endothelial systems * Signs and symptoms related to disorders of these systems * Other information determined by licensed health care professional to be necessary to determine increased risk <i>b)</i> Complete physical examination, with emphasis on liver, spleen, lymph nodes, skin <i>c)</i> CBC <i>d)</i> Other tests determined by licensed health care professional to be necessary to determine increased risk</p>
<p>Employees with past exposure to BD: \$ AL \$ 60 days/year for \$ 10 years <u>or</u> \$ PELs \$ 30 days/year for \$ 10 years <u>or</u> >10 ppm \$30 days in any past year</p>	<p><i>a)</i> Health questionnaire and CBC: annually <i>b)</i> Physical examination: * Initial exam * Every 3 years after initial * At discretion of licensed health care professional * At termination of employment if \$ 12 months since last exam</p>	<p>Same as above</p>
<p>Employees exposed to BD in an emergency situation</p>	<p>Within 48 hours after exposure</p>	<p><i>a)</i> CBC within 48 hours and then monthly for 3 months <i>b)</i> Physical exam if employee reports irritation of eyes, nose, throat, lungs, or skin; blurred vision; coughing; drowsiness; nausea; or headache <i>c)</i> Other medical screening at discretion of licensed health care professional</p>

Note: A CBC is performed on whole blood and includes a white blood cell count, hematocrit, red blood cell count, hemoglobin, differential count of white blood cells, red blood cell morphology, red blood cell indices, and platelet count.